Latest news from Amphista

Amphista Therapeutics showcases cryo-EM enabled platform for discovering novel Targeted Glue™ degraders at SLAS Europe 2025

Amphista Therapeutics to present novel mechanism of action for the degradation of BRD9 using its proprietary Targeted Glue® technology at two key upcoming scientific conferences

Amphista Therapeutics appoints Paul Medeiros as Chief Business Officer

Amphista Therapeutics appoints Antony Mattessich as Chief Executive Officer

The appointment will accelerate the Company’s next phase of growth, advancing its next generation Targeted Glue™ protein degraders into the clinic and building a robust pipeline

Amphista Therapeutics unveils new differentiated mechanism of action for BRD9 degradation at 2024 Protein Degradation in Focus Symposium

Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein degraders